Prosidion's future up in the air as Astellas begins assessing options
This article was originally published in Scrip
Executive Summary
Astellas has begun considering strategic options for the future of its UK R&D subsidiary Prosidion, which it acquired last year as part of the purchase of OSI Pharmaceuticals but now apparently considers surplus to its core interests.
You may also be interested in...
Shionogi's Oral COVID Drug Set For Global Access Through MPP
Agreement with UN-affiliated body set to expand global availability in lower income countries of Japanese firm’s protease inhibitor, which has faced approval road bumps at home but now looks set to move forward on positive new Phase III data.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: landmark results for lecanemab in Alzheimer’s; other Alzheimer’s players rise after the lecanemab results; Leqvio’s importance to Novartis; Pfizer’s secret sauce for digitalization; and Amgen’s clinical trial diversity efforts.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: a look at Alzheimer’s drug development; US-China decoupling irks Chinese biotech firms; seven potential blockbuster approvals in 2023; Novo Nordisk’s cardiovascular strategy; and a look at the vaccine and drug pipeline for monkeypox.